Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization

Abstract

In addition to a benign safety and robust humoral immunogenicity profile, subjects immunized with 2×10⁷ PFU elicited higher cellular immune responses and stronger interlocked cytokine networks compared to lower dose groups. To our knowledge these data represent the first detailed cell-mediated immuneprofile of a clinical trial testing rVSV-ZEBOV, which is of particular interest in light of its potential upcoming licensure as the first Ebola vaccine. VEBCON trial Hamburg, Germany (NCT02283099).